SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Björkhem I, Holmberg I 1978 Assay and properties of a mitochondrial 25-hydroxylase active on vitamin D. J Biol Chem 253:842849.
  • 2
    Saarem K, Bergseth S, Oftebro H, Pedersen JI 1984 Subcellular localization of vitamin D3 25-hydroxylase in human liver. J Biol Chem 259:1093610960.
  • 3
    Lawson DEM, Fraser DR, Kocdicek E, Morris HR, Williams DH 1971 Identification of 1,25-dihydroxycholecalciferol, a new kidney hormone controlling calcium metabolism. Nature 230:228230.
  • 4
    Holick MF, Schnoes HK, DeLuca HF 1971 Identification of 1,25-dihydroxycholecal-ciferol, a form of vitamin D3 metabolically active in the intestine. Proc Natl Acad Sci USA 68:803804.
  • 5
    Norman AW, Myrtle JF, Midgett RJ, Nowicki HG, Williams V, Popjak G 1971 1,25-Dihydroxycholecalciferol: Identification of the proposed active form of vitamin D3 in the intestine. Science 173:5154.
  • 6
    Holick MR, Schnoes HK, DeLuca HF, Gray RW, Boyle IT, Suda T 1972 Isolation and identification of 24,25-dihydroxycholecalciferol, a metabolite of vitamin D3 made in kidney. Biochemistry 11:45214255.
  • 7
    Sakaki T, Sawada N, Nonaka Y, Ohyama Y, Inouye K 1999 Metabolic studies using recombinant Escherichia coli cells producing rat mitochondrial CYP24: CYP24 can convert 1α,25-dihydroxyvitamin D3 to calcitroic acid. Eur J Biochem 262:4348.
  • 8
    Zimmerman DR, Reinhardt TA, Kremer R, Beitz DC, Reddy GS, Horst RL 2001 Calcitroic acid is a major catabolic metabolite in the metabolism of 1α,25-dihydroxyvitamin D2. Arch Biochem Biophys 392:1422.
  • 9
    Kamachi S, Sugimoto K, Yamasakis T, Hirose N, Ide H, Ohyama Y 2001 Metabolic activation of 1α-hydroxyvitamin D3 in human liver microsomes. Xenobiotica 31:701712.
  • 10
    Cali JJ, Russell DW 1991 Characterization of human sterol 27-hydroxylase. A mitochondrial cytochrome P-450 that catalyzes multiple oxidation reaction in bile acid biosynthesis. J Biol Chem 266:77747778.
  • 11
    Guo Y-D, Strugnell S, Back DW, Jones G 1993 Transfected human liver cytochrome P-450 hydroxylates vitamin D analogs at different side-chain positions. Proc Natl Acad Sci USA 90:86688672.
  • 12
    Cali JJ, Hsieh CL, Francke U, Russell DW 1991 Mutations in the bile acid biosynthetic enzyme sterol 27-hydroxylase underlie cerebrotendinous xanthomatosis. J Biol Chem 266:77797783.
  • 13
    Berginer VM, Shany S, Aklalay D, Berginer J, Dekel S, Salen G, Ting GS, Gazit D 1993 Osteoporosis and increased bone fractures in cerebrotendinous xanthomatosis. Metabolism 42:6974.
  • 14
    Chen KS, Prahl JM, DeLuca HF 1993 Isolation and expression of human 1,25-dihydroxyvitamin D3 24-hydroxylase cDNA. Proc Natl Acad Sci USA 90:45434547.
  • 15
    Fu GK, Lin D, Zhang MY, Bikle DD, Shackleton CH, Miller WL, Portale AA 1997 Cloning of human 25-hydroxyvitamin D-1 alpha-hydroxylase and mutations causing vita-min D-dependent rickets type 1. Mol Endocrinol 11:19611970.
  • 16
    Anonymous 2002 Human liver microsome assays. Available online at http://www:gentest.com/products/tissue_frac/prod_inserts/hlm_meth.shtml. Accessed on May 23, 2002.
  • 17
    Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzaon MD, Fujimo-to IK, Goeke NM, Olson BJ, Klenk DC 1985 Measurement of protein using bicinchoninic acid. Anal Biochem 150:7685.
  • 18
    Hollis BW 1997 Detection of vitamin D and its major metabolites. In: FeldmanDD, GlorieuxFH, PikeJW (eds.) Vitamin D. Academic Press, San Diego, CA, USA, pp. 587606.
  • 19
    Hollis BW, Kamerud JQ, Kurkowski A, Beaulieu J, Napoli JL 1996 Quantitation of circulating 1,25-dihydroxyvitamin D by radioimmunoassay with an 125I-labeled tracer. Clin Chem 42:586592.
  • 20
    Hollis BW, Kamerud JQ, Selvaag SR, Lorenz JD, Napoli JL 1993 Determination of vitamin D status with an 125I-labeled tracer. Clin Chem 39:529533.
  • 21
    Jones G 1986 A new pathway of 25-hydroxyvitamin D3 metabolism. Methods Enzymol 123:141154.
  • 22
    Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich P 1994 Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals; studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414423.
  • 23
    Lasker JM, Wester MR, Aramsombatdee E, Raucy JL 1998 Characterization of CYP2C19 and CYP2C9 from human liver: Respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations. Arch Biochem Biophys 353:1628.
  • 24
    Lasker JM, Chen WB, Wolf I, Bloswick BP, Wilson PD, Powell PK 2000 Formation of 20-hydroxyeicosatetraenoic acid, a vasoactive and natriuretic eicosanoid, in human kidney. J Biol Chem 275:41184126.
  • 25
    Roy P, Yu LJ, Crespi CL, Waxman DJ 1999 Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab Dispos 27:655666.
  • 26
    Ono S, Hatanaka T, Hotta H, Satoh T, Gonzalez FJ, Tsutsui M 1996 Specificity of substrate and inhibitor probes for cytochrome P450s: Evaluation of in vitro metabolism using cDNA-expressed human P450s and human liver microsomes. Xenobiotica 26:681693.
  • 27
    Desta Z, Soukhova NV, Flockhart DA 2001 Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid: Potent inhibition of CYP2C19 and CYP3A. Antimicrob Agents Chemother 45:382392.
  • 28
    Ghosal A, Satoh H, Thomas PE, Bush E, Moore D 1996 Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cDNA-expressed human cytochrome P450. Drug Metab Dispos 24:940947.
  • 29
    Ueng Y-F, Kuwabara T, Chun Y-J, Guengerich FP 1997 Cooperativity in oxidations catalyzed by cytochrome P450 3A4. Biochemistry 36:370381.
  • 30
    Giancarlo GM, Venkatakrishnan K, Granda BW, von Moltke LL, Greenblatt DJ 2001 Relative contributions of CYP2C9 and 2C19 to phenytoin 4-hydroxylation in vitro: Inhibition by sulfaphenazole, omeprazole, and ticlopidine. Eur J Clin Pharmacol 57:3136.
  • 31
    Schweikl H, Taylor JA, Kitareewan S, Linko P, Nagorney D, Goldstein JA 1993 Expression of CYP1A1 and CYP1A2 genes in human liver. Pharmacogenetics 3:239249.
  • 32
    Khuel P, Zhang P, Lin J, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Venkataramanan R, Strom S, Thummel K, Boguski MS, Schuetz E 2001 Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27:383391.
  • 33
    Burk O, Tegude H, Kock I, Hustert E, Wolbold R, Glaeser H, Klein K, Fromm MF, Nuessler AK, Neuhaus P, Zanger UM, Eichelbaum M, Wolnowski L 2002 Molecular mechanisms of polymorphic CYP3A7 expression in adult human liver and intestine. J Biol Chem 277:2428024288.
  • 34
    Drocourt L, Ourlin J-C, Pascussi J-M, Maurel P, Vilarem M-J 2002 Expression of CYP3A4, CYP2B6 and CYP2C9 is regulated by the vitamin D receptor pathway in primary human hepatocytes. J Biol Chem 277:2512525132.
  • 35
    Liddle C, Goodwin BJ, George J, Tapner M, Farrell GC 1998 Separate and interactive regulation of cytochrome P450 3A4 by triiodothyronine, dexamethasone, and growth hormone in cultured hepatocytes. J Clin Endocrinol Metab 83:24112416.
  • 36
    Theodoropoulos C, Demers C, Delvin E, Menard D, Gascon-Barre M 2003 Calcitriol regulates the expression of the genes encoding the three key vitamin D3 hydroxylases and the drug-metabolizing enzyme CYP3A4 in the human fetal intestine. Clin Endocrinol (Oxf) 58:489499.
  • 37
    Jaffe CA, Turgeon DK, Lown K, Demott-Friberg R, Watkins PB 2002 Growth hormone secretion pattern is an independent regulator of growth hormone actions in humans. Am J Physiol Endocrinol Metab 283:E1008E1015.
  • 38
    Hashimoto H, Toide K, Kitamura R, Fujita M, Tagawa S, Itoh S, Kamataki T 1993 Gene structure of CYP3A4, an adult-specific form of cytochrome P450 human livers, and its transcriptional control. Eur J Biochem 218:585595.
  • 39
    Schuetz JD, Beach DL, Guzelian PS 1994 Selective expression of cytochrome P450 CYP3A mRNAs in embryonic and adult human liver. Pharmacogenetics 4:1120.
  • 40
    Zhang CY, Dunbar D, Ostrowska A, Zeisloft S, Yang J, Kaminsky LS 1999 Characterization of human small intestinal cytochromes P-450. Drug Metab Dispos 27:804809.
  • 41
    de Wildt SN, Kearns GL, Leeder JS, van den Anker JN 1999 Cytochrome P450 3A: Ontogeny and drug disposition. Clin Pharmacokinet 37:485506.
  • 42
    Westlind A, Löfberg L, Tindberg N, Andersson TB, Ingel-Sundberg M 1999 Interindividual differences in hepatic expression of CYP3A4: Relationship to genetic polymorphism in the 5′-upstream regulatory region. Biochem Biophys Res Commun 259:201205.
  • 43
    Hollis BW, Pittard WB, Reinhardt TA 1986 Relationships among vitamin D, 25-hydroxyvitamin D-binding protein concentrations in the plasma and milk of humans. J Clin Endocrinol Metab 62:4144.
  • 44
    Jones G, Strugnell SA, DeLuca HF 1998 Current understanding of the molecular actions of vitamin D. Physiol Rev 78:11931231.
  • 45
    Brown AJ, Dusso AS, Slatopolsky E 2002 Vitamin D analogues for secondary hyperparathyroidism. Nephrol Dial Transplant 10(Suppl):1019.
  • 46
    Cheng JB, Motola DL, Mangelsdorf DJ, Russell DW 2003 Deorphanization of cytochrome P4502R1: A microsomal vitamin D-25-hydroxylase. J Biol Chem 278:3808438093.
  • 47
    Gibson GG, Plant NJ, Swales KE, Ayrton A, El-Sankary W 2002 Topics in xenobiochemistry. Receptor-dependent transcriptional activation of cytochrome P4503A genes: Induction mechanisms, species differences and interindividual variation in man. Xenobiotica 32:165206.
  • 48
    Venkatakrishnan K, von Moltke LL, Greenblatt DJ 2001 Human drug metabolism and the cytochromes P450: Application and relevance of in vitro methods. J Clin Pharmacol 41:11491170.
  • 49
    Dresser GK, Spence JD, Bailey DG 2000 Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 38:4157.
  • 50
    Sankary W, Plant NJ, Gibson GJ, Moore DJ 2000 Regulation of the CYP3A4 gene by hydrocortisone and xenobiotics: Role of the glucocorticoid and pregnane X receptors. Drug Metab Dispos 28:493496.
  • 51
    Lehmann JM, McKee DD, Watson MA, Willson TM, Moore JT, Kliewer SA 1998 The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest 102:10161023.
  • 52
    Bertilsson G, Heidrich J, Svensson K, Asman M, Jendeberg L, Sydow-Backman M, Ohlsson R, Postlind H, Blomquist P, Berkenstam A 1998 Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction. Proc Natl Acad Sci USA 95:1220812213.
  • 53
    Goodwin B, Hodgson E, Liddle C 1999 The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module. Mol Pharmacol 56:13291339.
  • 54
    Moore LB, Parks DJ, Jones SA, Bledso RK, Consler TG, Stimmel JB, Goodwin B, Liddle C, Blanchard SG, Willson TM, Collins TL, Kliewer SA 2000 Orphan nuclear receptors constitutive receptor and pregnane X receptor share xenobiotic and steroid ligands. J Biol Chem 275:1512215127.
  • 55
    Pascussi J-M, Gerbal-Chaloin S, Fabre J-M, Maurel P, Vilarem M-J 2000 Dexamethasone enhances constitutive androstane receptor expression in human hepatocytes: Consequences on cytochrome P450 gene regulation. Mol Pharmacol 58:14411450.
  • 56
    Brodie MJ, Boobis AR, Hillyard CJ, Abeyasekera G, MacIntyre I, Part BK 1981 Effect of isoniazid on vitamin D metabolism and hepatic monooxygenase activity. Clin Pharmacol Ther 30:362367.
  • 57
    Brodie MJ, Boobis AR, Dollery CT, Hillyard CJ, Brown DJ, MacIntyre I, Part BK 1980 Rifampicin and vitamin D metabolism. Clin Pharmacol Ther 27:810814.
  • 58
    Williams SE, Wardman AG, Taylor GA, Peacock M, Cooke NJ 1985 Long term study of the effect of rifampin and isoniazid on vitamin D metabolism. Tuberculosis (Edinb) 66:4954.
  • 59
    Jones DR, Gorski JC, Hamman MA, Mayhew BS, Rider S, Hall SD 1999 Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation. J Pharmacol Exp Ther 290:11161125.
  • 60
    Adams JS, Sharma OP, Diz MM, Endres DB 1990 Ketoconazole decreases the serum 1,25-dihydroxyvitamin D and calcium concentration in sarcoidosis-associated hypercalcemia. J Clin Endocrinol Metab 13:407413.
  • 61
    Hahn TJ, Hendin BA, Scharp CR, Haddad JG 1972 Effect of chronic anticonvulsant therapy on serum 25-hydroxycholecalciferol levels in adults. N Engl J Med 287:900904.
  • 62
    Sumi K, Sugita T, Shimotsuji T, Seino Y, Mimaki T, Yabuuchi H 1978 Effect of anticonvulsant therapy on serum 25-hydroxyvitamin D level. Tohoku J Exp Med 125:265269.
  • 63
    Hahn TJ, Birge SJ, Scharp CR, Avioli LV 1972 Phenobarbital-induced alterations in vitamin D metabolism. J Clin Invest 51:748751.
  • 64
    Kamachi S, Sugimoto K, Yamasaki T, Hirose N, Ide H, Ohyama Y 2001 Metabolic activation of 1α-hydroxyvitamin D3 in human liver microsomes. Xenobiotica 10:701712.